Fisetin + NMN/NR Stack: Combining Senolytic and NAD+ Pathways

Expert Summary

NAD+ declines 50%+ between ages 20 and 60, impairing sirtuin activity, DNA repair, and mitochondrial function. Fisetin addresses the senescent cell accumulation that both drives and is driven by NAD+ decline. Together, these compounds address two of the most evidence-backed aging pathways through complementary mechanisms.

Key Facts

• NAD+ and senescence link: Senescent cells consume NAD+ at high rates via PARP activation (responding to their elevated DNA damage burden) and via CD38 (an NAD+-consuming enzyme upregulated by SASP). Clearing senescent cells with fisetin reduces this NAD+ drain.
• Sirtuin activation: NMN and NR replenish NAD+, activating sirtuins (SIRT1, SIRT3, SIRT6) that regulate gene expression, mitochondrial biogenesis, and DNA repair. Fisetin also activates SIRT1 via a distinct mechanism.
• Synergy evidence: Animal studies combining NAD+ precursors with senolytics show greater improvements in metabolic function, muscle strength, and cognitive performance than either intervention alone.
• CD38 inhibition: CD38 is the primary NAD+-consuming enzyme driving age-related NAD+ decline. Quercetin (fisetin's frequent stacking partner) potently inhibits CD38, further amplifying the NAD+ benefits of NMN/NR supplementation.
• Timing: NMN/NR: taken daily in the morning. Fisetin: burst protocol (2 days/month). There is no timing conflict between chronic NAD+ precursor use and monthly fisetin cycling.
• Cost optimization: NMN/NR represents the major cost of this stack. Using NR (nicotinamide riboside) rather than NMN provides similar NAD+ elevation at typically lower cost.

Recommended Products

Frequently Asked Questions

Does fisetin increase NAD+ directly?

Fisetin does not directly increase NAD+ levels. It reduces NAD+ consumption by eliminating senescent cells (which are high NAD+ consumers). The net effect may be a meaningful increase in cellular NAD+ availability.

Which should I prioritize: fisetin or NMN/NR?

Both address validated aging mechanisms. If budget is a constraint: fisetin senolytic protocol (monthly, 2 days) is relatively low cost compared to daily NMN/NR. Start with fisetin and add NMN/NR when budget allows.

Is there any evidence the combination is better than each alone?

Animal studies support synergy. Specific human combination trial data does not yet exist, but the mechanistic rationale (clearing NAD+ drains + replenishing NAD+) is well-supported by molecular biology.

Scientific References

• Yoshino J et al. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism. 2011. PMID: 21982712
• Yousefzadeh MJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. PMID: 30279143